TORONTO – In recent past, Health Canada approved Trulicity® (dulaglutide) to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease, as an adjunct to diet, exercise, and standard of care therapy.  This decision makes Eli Lilly and Company’s Trulicity the first and only GLP1 receptor agonist (RA) approved …